---
title: "Ifupinostat phase 2 trial in relapsed/refractory DLBCL: study report and open questions"
id: "pubmed-42893991"
canonical_url: "https://medichelpline.com/clinical-feed/pubmed-42893991"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "PubMed / NCBI"
source_url: "https://pubmed.ncbi.nlm.nih.gov/42893991/"
doi: "10.1038/s41392-026-02926-8"
published_at: "2026-10-19T00:00:00.000Z"
evidence_level: "Journal Article"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Ifupinostat phase 2 trial in relapsed/refractory DLBCL: study report and open questions
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/pubmed-42893991
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** PubMed / NCBI
- **Source URL:** [Original Journal Publication](https://pubmed.ncbi.nlm.nih.gov/42893991/)
- **DOI:** [10.1038/s41392-026-02926-8](https://doi.org/10.1038%2Fs41392-026-02926-8)
- **Published At:** 2026-10-19T00:00:00.000Z
- **Evidence Rating:** Journal Article
## Executive GIST (TL;DR)
- The publication reports a multicenter, single-arm **phase 2** clinical trial of **ifupinostat** in relapsed or refractory **diffuse large B-cell lymphoma** (DLBCL). - The article is authored by Yuankai Shi and collaborators across numerous Chinese cancer centers and industry partner BeBetter Med Inc.; equal contribution by two first authors was indicated. - Journal metadata: Signal Transduct Target Ther, 2026 Oct 19;11(1):466; DOI 10.1038/s41392-026-02926-8; PubMed ID 42893991. - The PubMed page provided title, author list, affiliations, and bibliographic identifiers but did not include the trial’s numeric results, response rates, survival data, dosing regimen, or adverse event tables in the captured content. - The source excerpt did not report sample size, eligibility criteria, primary and secondary endpoints, statistical methods, or specific safety signals; those methodological details are therefore not available in this source text. - Given the metadata-only capture on PubMed, readers must consult the full text (journal DOI) for efficacy outcomes, toxicity profiles, and protocol specifics to evaluate clinical utility and external validity. - Key unanswered clinical questions from the provided record: What were objective response rate, complete response rate, progression-free survival and overall survival? What was the ifupinostat dosing schedule and duration? What grade ≥3 adverse events occurred? Were correlative biomarkers or histologic subgroups analyzed? - The available record establishes provenance and multicenter involvement but leaves clinical interpretation dependent on the full published manuscript and supplemental materials.
## Clinical Analysis & Structured Key Points
Clipboard, Search History, and several other advanced features are temporarily unavailable. [ Skip to main page content ](https://pubmed.ncbi.nlm.nih.gov/42893991/#article-details) ![U.S. flag](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png) An official website of the United States government Here's how you know ![Dot gov](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg) **The .gov means it’s official.** Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. ![Https](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg) **The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. [ ![NIH NLM Logo](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg) ](https://www.ncbi.nlm.nih.gov/) [Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42893991%2F) Show account info Close #### Account Logged in as: **username** * [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/) * [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/) * [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/) * [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/42893991/) [Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys) [NCBI Homepage](https://www.ncbi.nlm.nih.gov) [MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/) [Main Content](https://pubmed.ncbi.nlm.nih.gov/42893991/#maincontent) [Main Navigation](https://pubmed.ncbi.nlm.nih.gov/42893991/) [ ![pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/a447896c-976f-490b-b86b-2668b65114a8/core/images/pubmed-logo-blue.svg) ](https://pubmed.ncbi.nlm.nih.gov/) [ ](https://pubmed.ncbi.nlm.nih.gov/42893991/ "Show search bar") Search: [](https://pubmed.ncbi.nlm.nih.gov/42893991/ "Clear search input")Search [Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/) [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/clipboard/) [ User Guide ](https://pubmed.ncbi.nlm.nih.gov/help/) Save Email Send to * [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/42893991/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42893991%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42893991%2F%23open-collections-panel) * [Citation manager](https://pubmed.ncbi.nlm.nih.gov/42893991/) Display options Display options Format Abstract PubMed PMID ## Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel ## Email citation Email address has not been verified. Go to [ My NCBI account settings ](https://account.ncbi.nlm.nih.gov/settings/) to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel ### Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42893991/) Add Cancel ### Add to My Bibliography * My Bibliography Unable to load your delegates due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42893991/) Add Cancel ## Your saved search Name of saved search: Search terms: [Test search terms](https://pubmed.ncbi.nlm.nih.gov/42893991/) Would you like email updates of new search results? Saved Search Alert Radio Buttons * Yes * No Email: ([change](https://www.ncbi.nlm.nih.gov/account/settings/)) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel ## Create a file for external citation management software Create file Cancel ## Your RSS Feed Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy ### Actions Cite Collections Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42893991/) Add Cancel Permalink Permalink Copy Display options Display options Format Abstract PubMed PMID ### Experimental Resource Linked Discoveries ### Page navigation * [ Title & authors ](https://pubmed.ncbi.nlm.nih.gov/42893991/#heading) * [ Abstract ](https://pubmed.ncbi.nlm.nih.gov/42893991/#abstract) * [ Conflict of interest statement ](https://pubmed.ncbi.nlm.nih.gov/42893991/#conflict-of-interest) * [ References ](https://pubmed.ncbi.nlm.nih.gov/42893991/#references) * [ Publication types ](https://pubmed.ncbi.nlm.nih.gov/42893991/#publication-types) * [ MeSH terms ](https://pubmed.ncbi.nlm.nih.gov/42893991/#mesh-terms) * [ Substances ](https://pubmed.ncbi.nlm.nih.gov/42893991/#substances) Title & authors Abstract Conflict of interest statement References Publication types MeSH terms Substances Clinical Trial Signal Transduct Target Ther Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Signal+Transduct+Target+Ther%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Signal+Transduct+Target+Ther%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42893991/) . 2026 Oct 19;11(1):466. doi: 10.1038/s41392-026-02926-8. # Efficacy and safety of ifupinostat in relapsed or refractory diffuse large B-cell lymphoma: a multicenter, single-arm phase 2 study [Yuankai Shi](https://pubmed.ncbi.nlm.nih.gov/?term=Shi+Y&cauthor_id=42893991)[#](https://pubmed.ncbi.nlm.nih.gov/42893991/#full-view-equal-contrib-explanation "Contributed equally")[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42893991/#full-view-affiliation-1 "Department of Medical Oncology, Beijing Key Laboratory of Key Technologies for Early Clinical Trial Evaluation of Innovative Drugs for Major Diseases, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, PR China. syuankai@cicams.ac.cn."), [Peng Liu](https://pubmed.ncbi.nlm.nih.gov/?term=Liu+P&cauthor_id=42893991)[#](https://pubmed.ncbi.nlm.nih.gov/42893991/#full-view-equal-contrib-explanation "Contributed equally")[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42893991/#full-view-affiliation-2 "Department of Medical Oncology, Beijing Key Laboratory of Key Technologies for Early Clinical Trial Evaluation of Innovative Drugs for Major Diseases, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, PR China."), [Yufu Li](https://pubmed.ncbi.nlm.nih.gov/?term=Li+Y&cauthor_id=42893991)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42893991/#full-view-affiliation-3 "Hematology Department, Henan Cancer Hospital, Henan, PR China."), [Wenyu Li](https://pubmed.ncbi.nlm.nih.gov/?term=Li+W&cauthor_id=42893991)[ 4 ](https://pubmed.ncbi.nlm.nih.gov/42893991/#full-view-affiliation-4 "Lymphoma Department, Guangdong Provincial People's Hospital, Guangdong, PR China."), [Hui Zhou](https://pubmed.ncbi.nlm.nih.gov/?term=Zhou+H&cauthor_id=42893991)[ 5 ](https://pubmed.ncbi.nlm.nih.gov/42893991/#full-view-affiliation-5 "Lymphoma Hematology Department, Hunan Cancer Hospital, Hunan, PR China."), [Yu Yang](https://pubmed.ncbi.nlm.nih.gov/?term=Yang+Y&cauthor_id=42893991)[ 6 ](https://pubmed.ncbi.nlm.nih.gov/42893991/#full-view-affiliation-6 "Lymphoma and Head and Neck Tumor Department, Fujian Cancer Hospital, Fujian, PR China."), [Jie Jin](https://pubmed.ncbi.nlm.nih.gov/?term=Jin+J&cauthor_id=42893991)[ 7 ](https://pubmed.ncbi.nlm.nih.gov/42893991/#full-view-affiliation-7 "Hematology Department, The First Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang, PR China."), [Yuhuan Gao](https://pubmed.ncbi.nlm.nih.gov/?term=Gao+Y&cauthor_id=42893991)[ 8 ](https://pubmed.ncbi.nlm.nih.gov/42893991/#full-view-affiliation-8 "Hematology Department, Hebei Cancer Hospital, Hebei, PR China."), [Weijie Xu](https://pubmed.ncbi.nlm.nih.gov/?term=Xu+W&cauthor_id=42893991)[ 9 ](https://pubmed.ncbi.nlm.nih.gov/42893991/#full-view-affiliation-9 "Oncology Department, Jilin Cancer Hospital, Jilin, PR China."), [Meifang Zheng](https://pubmed.ncbi.nlm.nih.gov/?term=Zheng+M&cauthor_id=42893991)[ 10 ](https://pubmed.ncbi.nlm.nih.gov/42893991/#full-view-affiliation-10 "Internal Medicine Department, Linyi Cancer Hospital, Shandong, PR China."), [Haiyan Yang](https://pubmed.ncbi.nlm.nih.gov/?term=Yang+H&cauthor_id=42893991)[ 11 ](https://pubmed.ncbi.nlm.nih.gov/42893991/#full-view-affiliation-11 "Lymphoma Department, Zhejiang Cancer Hospital, Zhejiang, PR China."), [Hongwei Xue](https://pubmed.ncbi.nlm.nih.gov/?term=Xue+H&cauthor_id=42893991)[ 12 ](https://pubmed.ncbi.nlm.nih.gov/42893991/#full-view-affiliation-12 "Hematology Department, The Affiliated Hospital of Qingdao University, Shandong, PR China."), [Zhigang Peng](https://pubmed.ncbi.nlm.nih.gov/?term=Peng+Z&cauthor_id=42893991)[ 13 ](https://pubmed.ncbi.nlm.nih.gov/42893991/#full-view-affiliation-13 "Oncology Department, The First Affiliated Hospital of Guangxi Medical University, Guangxi, PR China."), [Ou Bai](https://pubmed.ncbi.nlm.nih.gov/?term=Bai+O&cauthor_id=42893991)[ 14 ](https://pubmed.ncbi.nlm.nih.gov/42893991/#full-view-affiliation-14 "Hematology Department, The First Hospital of Jilin University, Jilin, PR China."), [Fei Li](https://pubmed.ncbi.nlm.nih.gov/?term=Li+F&cauthor_id=42893991)[ 15 ](https://pubmed.ncbi.nlm.nih.gov/42893991/#full-view-affiliation-15 "Hematology Department, The First Affiliated Hospital of Nanchang University, Jiangxi, PR China."), [Fangfang Lv](https://pubmed.ncbi.nlm.nih.gov/?term=Lv+F&cauthor_id=42893991)[ 16 ](https://pubmed.ncbi.nlm.nih.gov/42893991/#full-view-affiliation-16 "Oncology Department, Fudan University Shanghai Cancer Center, Shanghai, PR China."), [Liling Zhang](https://pubmed.ncbi.nlm.nih.gov/?term=Zhang+L&cauthor_id=42893991)[ 17 ](https://pubmed.ncbi.nlm.nih.gov/42893991/#full-view-affiliation-17 "Lymphoma Department, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei, PR China."), [Ning Huang](https://pubmed.ncbi.nlm.nih.gov/?term=Huang+N&cauthor_id=42893991)[ 18 ](https://pubmed.ncbi.nlm.nih.gov/42893991/#full-view-affiliation-18 "Hematology Department, Shandong Provincial Qianfoshan Hospital, Shandong, PR China."), [Yi Luo](https://pubmed.ncbi.nlm.nih.gov/?term=Luo+Y&cauthor_id=42893991)[ 19 ](https://pubmed.ncbi.nlm.nih.gov/42893991/#full-view-affiliation-19 "Oncology Department, Changsha Kexin Cancer Hospital, Hunan, PR China."), [Chunhong Hu](https://pubmed.ncbi.nlm.nih.gov/?term=Hu+C&cauthor_id=42893991)[ 20 ](https://pubmed.ncbi.nlm.nih.gov/42893991/#full-view-affiliation-20 "Oncology Department, The Second Xiangya Hospital of Central South University, Hunan, PR China."), [Yajing Xu](https://pubmed.ncbi.nlm.nih.gov/?term=Xu+Y&cauthor_id=42893991)[ 21 ](https://pubmed.ncbi.nlm.nih.gov/42893991/#full-view-affiliation-21 "Hematology Department, Xiangya Hospital of Central South University, Hunan, PR China."), [Huilai Zhang](https://pubmed.ncbi.nlm.nih.gov/?term=Zhang+H&cauthor_id=42893991)[ 22 ](https://pubmed.ncbi.nlm.nih.gov/42893991/#full-view-affiliation-22 "Lymphoma Department, Tianjin Medical University Cancer Institute & Hospital, Tianjin, PR China."), [Xiuhua Sun](https://pubmed.ncbi.nlm.nih.gov/?term=Sun+X&cauthor_id=42893991)[ 23 ](https://pubmed.ncbi.nlm.nih.gov/42893991/#full-view-affiliation-23 "Oncology Department, The Second Hospital of DaLian Medical University, Liaoning, PR China."), [Xin Li](https://pubmed.ncbi.nlm.nih.gov/?term=Li+X&cauthor_id=42893991)[ 24 ](https://pubmed.ncbi.nlm.nih.gov/42893991/#full-view-affiliation-24 "Oncology Department, The First Affiliated Hospital of Zhengzhou University, Henan, PR China."), [Kaiyang Ding](https://pubmed.ncbi.nlm.nih.gov/?term=Ding+K&cauthor_id=42893991)[ 25 ](https://pubmed.ncbi.nlm.nih.gov/42893991/#full-view-affiliation-25 "Hematological Oncology Department, Anhui Provincial Cancer Hospital, Anhui, PR China."), [Linjuan Zeng](https://pubmed.ncbi.nlm.nih.gov/?term=Zeng+L&cauthor_id=42893991)[ 26 ](https://pubmed.ncbi.nlm.nih.gov/42893991/#full-view-affiliation-26 "Oncology Department, The Fifth Affiliated Hospital Sun Yat-san University, Guangdong, PR China."), [Haiyan Zhu](https://pubmed.ncbi.nlm.nih.gov/?term=Zhu+H&cauthor_id=42893991)[ 27 ](https://pubmed.ncbi.nlm.nih.gov/42893991/#full-view-affiliation-27 "Radiation Injury Treatment Department, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, PR China."), [Yajie Cao](https://pubmed.ncbi.nlm.nih.gov/?term=Cao+Y&cauthor_id=42893991)[ 28 ](https://pubmed.ncbi.nlm.nih.gov/42893991/#full-view-affiliation-28 "Center of Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Changsha, PR China.")[ 29 ](https://pubmed.ncbi.nlm.nih.gov/42893991/#full-view-affiliation-29 "BeBetter Med Inc., Guangzhou, Guangdong, PR China."), [Yonglong Yang](https://pubmed.ncbi.nlm.nih.gov/?term=Yang+Y&cauthor_id=42893991)[ 29 ](https://pubmed.ncbi.nlm.nih.gov/42893991/#full-view-affiliation-29 "BeBetter Med Inc., Guangzhou, Guangdong, PR China."), [Kegang Jiang](https://pubmed.ncbi.nlm.nih.gov/?term=Jiang+K&cauthor_id=42893991)[ 29 ](https://pubmed.ncbi.nlm.nih.gov/42893991/#full-view-affiliation-29 "BeBetter Med Inc., Guangzhou, Guangdong, PR China."), [Changgeng Qian](https://pubmed.ncbi.nlm.nih.gov/?term=Qian+C&cauthor_id=42893991)[ 29 ](https://pubmed.ncbi.nlm.nih.gov/42893991/#full-view-affiliation-29 "BeBetter Med Inc., Guangzhou, Guangdong, PR China.") Affiliations Expand ### Affiliations * 1 Department of Medical Oncology, Beijing Key Laboratory of Key Technologies for Early Clinical Trial Evaluation of Innovative Drugs for Major Diseases, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, PR China. syuankai@cicams.ac.cn. * 2 Department of Medical Oncology, Beijing Key Laboratory of Key Technologies for Early Clinical Trial Evaluation of Innovative Drugs for Major Diseases, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, PR China. * 3 Hematology Department, Henan Cancer Hospital, Henan, PR China. * 4 Lymphoma Department, Guangdong Provincial People's Hospital, Guangdong, PR China. * 5 Lymphoma Hematology Department, Hunan Cancer Hospital, Hunan, PR China. * 6 Lymphoma and Head and Neck Tumor Department, Fujian Cancer Hospital, Fujian, PR China. * 7 Hematology Department, The First Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang, PR China. * 8 Hematology Department, Hebei Cancer Hospital, Hebei, PR China. * 9 Oncology Department, Jilin Cancer Hospital, Jilin, PR China. * 10 Internal Medicine Department, Linyi Cancer Hospital, Shandong, PR China. * 11 Lymphoma Department, Zhejiang Cancer Hospital, Zhejiang, PR China. * 12 Hematology Department, The Affiliated Hospital of Qingdao University, Shandong, PR China. * 13 Oncology Department, The First Affiliated Hospital of Guangxi Medical University, Guangxi, PR China. * 14 Hematology Department, The First Hospital of Jilin University, Jilin, PR China. * 15 Hematology Department, The First Affiliated Hospital of Nanchang University, Jiangxi, PR China. * 16 Oncology Department, Fudan University Shanghai Cancer Center, Shanghai, PR China. * 17 Lymphoma Department, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei, PR China. * 18 Hematology Department, Shandong Provincial Qianfoshan Hospital, Shandong, PR China. * 19 Oncology Department, Changsha Kexin Cancer Hospital, Hunan, PR China. * 20 Oncology Department, The Second Xiangya Hospital of Central South University, Hunan, PR China. * 21 Hematology Department, Xiangya Hospital of Central South University, Hunan, PR China. * 22 Lymphoma Department, Tianjin Medical University Cancer Institute & Hospital, Tianjin, PR China. * 23 Oncology Department, The Second Hospital of DaLian Medical University, Liaoning, PR China. * 24 Oncology Department, The First Affiliated Hospital of Zhengzhou University, Henan, PR China. * 25 Hematological Oncology Department, Anhui Provincial Cancer Hospital, Anhui, PR China. * 26 Oncology Department, The Fifth Affiliated Hospital Sun Yat-san University, Guangdong, PR China. * 27 Radiation Injury Treatment Department, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, PR China. * 28 Center of Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Changsha, PR China. * 29 BeBetter Med Inc., Guangzhou, Guangdong, PR China. # Contributed equally. * PMID: **42893991** * DOI: [ 10.1038/s41392-026-02926-8 ](https://doi.org/10.1038/s41392-026-02926-8) Item in Clipboard Clinical Trial # Efficacy and safety of ifupinostat in relapsed or refractory diffuse large B-cell lymphoma: a multicenter, single-arm phase 2 study Yuankai Shi et al. Signal Transduct Target Ther. 2026. Show details Display options Display options Format Abstract PubMed PMID Signal Transduct Target Ther Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Signal+Transduct+Target+Ther%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Signal+Transduct+Target+Ther%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42893991/) . 2026 Oct 19;11(1):466. doi: 10.1038/s41392-026-02926-8. ### Authors [Yuankai Shi](https://pubmed.ncbi.nlm.nih.gov/?term=Shi+Y&cauthor_id=42893991)[#](https://pubmed.ncbi.nlm.nih.gov/42893991/#short-view-equal-contrib-explanation "Contributed equally")[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42893991/#short-view-affiliation-1 "Department of Medical Oncology, Beijing Key Laboratory of Key Technologies for Early Clinical Trial Evaluation of Innovative Drugs for Major Diseases, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, PR China. syuankai@cicams.ac.cn."), [Peng Liu](https://pubmed.ncbi.nlm.nih.gov/?term=Liu+P&cauthor_id=42893991)[#](https://pubmed.ncbi.nlm.nih.gov/42893991/#short-view-equal-contrib-explanation "Contributed equally")[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42893991/#short-view-affiliation-2 "Department of Medical Oncology, Beijing Key Laboratory of Key Technologies for Early Clinical Trial Evaluation of Innovative Drugs for Major Diseases, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, PR China."), [Yufu Li](https://pubmed.ncbi.nlm.nih.gov/?term=Li+Y&cauthor_id=42893991)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42893991/#short-view-
## Related Clinical Research

- [Naive-like T cell proportion predicts durable response to axi-cel in lymphoma](https://medichelpline.com/clinical-feed/nature-1-determinants-of-response-to-car-t-cell-therapy-in-a-multicenter-multi-trial.md)
- [No prognostic value of c-MET, HLA class II, or CD68 by IHC in early-stage classic Hodgkin lymphoma](https://medichelpline.com/clinical-feed/plos-one-14-immunohistochemistry-for-c-met-hla-class-ii-and-cd68-does-not-show-prognostic.md)
- [mRNA LNP co-delivery of autoactivated cGAS and membrane-tethered IL-12 induces systemic tumor cont](https://medichelpline.com/clinical-feed/biorxiv-1-combining-an-autoactivated-cgas-mutant-with-membrane-tethered-il-12-via-mrna.md)
- [ComBat outperforms alternatives for cross-batch prediction in B‑cell lymphoma harmonization](https://medichelpline.com/clinical-feed/biorxiv-14-2-234-attempts-to-harmonize-a-multi-platform-b-cell-lymphoma-bulk.md)
- [Sintilimab plus R-CHOP vs DA-EPOCH-R in PMBCL — article content unavailable on source page](https://medichelpline.com/clinical-feed/frontiers-in-immunology-15-sintilimab-plus-r-chop-versus-da-epoch-r-as-first-line-therapy-for-primary.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.